Wei Li, Luo Rong-cheng, Zhang Jun-yi, Yan Xiao, Fang Yong-xin, Fei Li-hua
Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2006 Feb;26(2):211-3.
To study the biological response of B-cell lymphoma cells positive for CD20 expression to (131)I-labeled rituximab.
Anti-CD20 monoclonal antibody rituximab was labeled with (131)I by means of IODO-GEN method, and its effects on apoptosis of Raji cells were determined by Annexin-V/PI double-labeled cytometry. Its effects on the cell cycles was evaluated by cytometry with PI staining.
The cell apoptosis rate measured by Annexin v-FITC/PI was 51.99% in (131)I-rituximab group, significantly higher than that in (131)I group, rituximab group and control group (42.71%, 29.42% and 26.17%, respectively, P<;0.05). The apoptosis rate by flow cytometry with PI staining was 4.32% in (131)I-rituximab group, also significantly higher than that in the other 3 groups (1.47%, 1.39% and 0.37%, respectively, P<0.05). Cell cycle alteration of Raji cells occurred in (131)I-rituximab group, and the majority of cells were arrested at G(1)/G(2) stage.
(131)I-rituximab can regulate the cell cycle of Raji cells and induce their apoptosis to inhibit their proliferation.
研究CD20表达阳性的B细胞淋巴瘤细胞对¹³¹I标记的利妥昔单抗的生物学反应。
采用IODO-GEN法用¹³¹I标记抗CD20单克隆抗体利妥昔单抗，通过Annexin-V/PI双标记流式细胞术检测其对Raji细胞凋亡的影响。用PI染色流式细胞术评估其对细胞周期的影响。
Annexin v-FITC/PI检测¹³¹I-利妥昔单抗组细胞凋亡率为51.99%，显著高于¹³¹I组、利妥昔单抗组和对照组（分别为42.71%、29.42%和26.17%，P<0.05）。PI染色流式细胞术检测¹³¹I-利妥昔单抗组凋亡率为4.32%，也显著高于其他3组（分别为1.47%、1.39%和0.37%，P<0.05）。¹³¹I-利妥昔单抗组Raji细胞出现细胞周期改变，大多数细胞停滞在G₁/G₂期。
¹³¹I-利妥昔单抗可调节Raji细胞的细胞周期并诱导其凋亡以抑制其增殖。
